Ricerca Names Thomas Davidson, Ph.D., as Director of Toxicology and Pharmacology

CONCORD, Ohio--(BUSINESS WIRE)--Thomas Davidson, Ph.D., has joined Ricerca as the director of toxicology and pharmacology. Dr. Davidson is responsible for the work performed by Ricerca study directors, peer review of toxicological reports and ensuring on-time delivery of these reports.

Dr. Davidson brings significant capabilities and expertise to Ricerca. Prior to joining Ricerca, Dr. Davidson was the director of toxicology at Enzon Pharmaceuticals, Inc. in Piscataway, New Jersey. In addition, he previously was Executive Director – Drug Safety Evaluation at Bristol-Myers Squibb (BMS) in New Brunswick, New Jersey. Dr. Davidson also held previous roles as the director, associate director and group leader for the Department of Biologics Evaluation at BMS in Syracuse, New York.

“Tom has an extensive background in conducting toxicology and pharmacology studies which will benefit our clients,” said Ian Lennox, Chairman and CEO, Ricerca. "Tom Davidson’s addition to Ricerca as director of toxicology represents a significant milestone in our continued growth of toxicology as an essential element of Ricerca's strategy and continued success in meeting or exceeding our clients’ expectations of advancing their preclinical compounds with timely and high quality toxicology study results."

Dr. Davidson received his Bachelor of Arts in Natural Science from Goshen College and his Ph.D. in Pathology from the University of Wisconsin.

About Ricerca Biosciences

Ricerca is the only North American CRO that takes pharmaceutical and biotech companies straight through from IP to IND. Our state-of-the-art facility combined with over 300 scientists and support staff provides all of the discovery and development services required to bring target or drug candidates to complete IND submission. Ricerca’s unique ability to seamlessly integrate chemistry and biology, along with report writing and regulatory services at one location, allows companies to achieve their preclinical destination—faster and without any detours.